Targeting the DDR through Chk1 inhibition, therefore, represents a novel therapeutic strategy to increase DNA-damaging chemotherapeutic drug induced tumor cell death in p53 pathway defective cancers [9,10] by abrogating the remaining intact checkpoint. The gene discussed is TP53; the disease is cancer.